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SHP2Noonan syndrome (NS) is an autosomal dominant disorder, and a main feature is congenital heart
malformation. About 50% of cases are caused by gain-of-function mutations in the tyrosine phosphatase
SHP2/PTPN11, a downstream regulator of ERK/MAPK. Recently it was reported that SHP2 also localizes to the
mitochondrial intercristae/intermembrane space (IMS), but the role of SHP2 in mitochondria is unclear. The
mitochondrial oxidative phosphorylation (OxPhos) system provides the vast majority of cellular energy and
produces reactive oxygen species (ROS). Changes in ROS may interfere with organ development such as that
observed in NS patients. Several phosphorylation sites have been found in OxPhos components including
cytochrome c oxidase (CcO) and cytochrome c (Cytc), and we hypothesized that OxPhos complexes may be
direct or indirect targets of SHP2. We analyzed mitochondrial function using mouse ﬁbroblasts from wild-
types, SHP2 knockdowns, and D61G SHP2 mutants leading to constitutively active SHP2, as found in NS
patients. Levels of OxPhos complexes were similar except for CcO and Cytc, which were 37% and 28% reduced
in the D61G cells. However, CcO activity was signiﬁcantly increased, as we also found for two lymphoblast
cell lines from NS patients with two independent mutations in PTPN11. D61G cells showed lower
mitochondrial membrane potential and 30% lower ATP content compared to controls. ROS were signiﬁcantly
increased; aconitase activity, a marker for ROS-induced damage, was decreased; and catalase activity was
increased in D61G cells. We propose that decreased energy levels and/or increased ROS may explain, at least
in part, some of the clinical features in NS that overlap with children with mitochondrial disorders.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
SHP2 is a ubiquitously expressed non-receptor protein tyrosine
phosphatase (PTP) [1]. SHP2 is involved in several cellular processes
including cell development, growth, and survival, and it is thus a central
player in important signaling pathways, including mitogen-activated
protein kinase (MAPK) and Janus-tyrosine kinase 2 (Jak2)/signal
transducer and activator of transcription (STAT) signaling [2]. SHP2 is
encoded by the gene PTPN11 and contains two N-terminal Src-
homology 2 (SH2) domains and a central tyrosine phosphatase domain.
The C-terminal region contains two regulatory tyrosine phosphoryla-
tion sites required for full downstream activation of theMAPK pathway
via ﬁbroblast growth factor-, platelet-derived growth factor-, but not
epidermal growth factor-triggered signaling [3]. Mice homozygous for
dysfunctional SHP2, which lack the N-terminal SH2 domain requiredchrome c; CS, citrate synthase;
; KD, knockdown; NS, Noonan
d-type
+1 313 577 5218.
nn).
ll rights reserved.for phosphotyrosine recognition but with a functional phosphatase
domain, die beforeE.11.5 of gestation [4],whereas PTPN11nullmicedie
signiﬁcantly earlier during the peri-implantation period [5].
Mutations in PTPN11 can cause Noonan syndrome (NS), the related
LEOPARD syndrome, and leukemia. NS mutations usually lead to
constitutively active SHP2. For example, theNS-causingmutationD61G
results in about 10-fold increased basal SHP2 activity, whereas the
leukemia causing D61Y mutation leads to an about 20-fold increased
basal activity [6]. With an incidence of 1:1000 to 1:2500 live births, NS
is a common cause of congenital heart disease. NS features include
heart abnormalities, short stature, characteristic facies, hypotonia,
developmental delay, learning problems, and leukemia predisposition.
Gain-of-function mutations in PTPN11 cause approximately 50% of
Noonan syndrome cases [7]. Mutations in other genes that are part of
the MAPK pathway have also been identiﬁed in NS patients, such as
gain-of-function mutations in the RAS guanine nucleotide-exchange
factor SOS1, which account for approximately 10% of NS cases [8].
In addition to being a central constituent of receptor tyrosine
kinase signaling near the plasma membrane, SHP2 was recently
reported to also localize tomitochondria derived from rat brain [9,10],
speciﬁcally to the intercristae/intermembrane space (IMS). A possible
276 I. Lee et al. / Biochimica et Biophysica Acta 1802 (2010) 275–283direct or indirect substrate of SHP2 is a central unit of enzymes that is
housed in the inner mitochondrial membrane, the oxidative phos-
phorylation (OxPhos) machinery. It consists of the electron transport
chain (ETC) and ATP synthase. The ETC is a series of electron
transferring moieties consisting of NADH dehydrogenase (complex I),
succinate dehydrogenase (SDH; complex II), ubiquinone, bc1-complex
(complex III), cytochrome c (Cytc), and cytochrome c oxidase (CcO;
complex IV). Electron transport in the ETC complexes I, III, and IV is
coupled to proton pumping, which generates the mitochondrial
proton membrane potential ΔΨm across the inner mitochondrial
membrane. ΔΨm is utilized by ATP synthase (complex V) to
synthesize ATP from ADP and phosphate via the backﬂow of protons
from the mitochondrial IMS to the matrix. Through aerobic respira-
tion, OxPhos is responsible for more than 90% of cellular energy
production. In addition, it is a major producer of reactive oxygen
species (ROS). Since a lack of energy and/or increased ROS are
increasingly associated with numerous human diseases, we hypo-
thesized that mutations of SHP2 as found in NS may affect mito-
chondrial function. In addition, ROS are involved in cell signaling and
perturbations of ROS levels might contribute to organ maldevelop-
ment as found in NS patients.
Recently, newmodels havebeenpresented to explain the regulation
of mitochondrial energy and ROS production. In the traditional view,
which is mainly based on studies in bacteria, the activity of the ETC
proton pumps is regulated by the mitochondrial membrane potential
ΔΨm, which at high levels inhibits further proton pumping. The
Kadenbach group has shown that CcO is allosterically regulated by the
ATP/ADP ratio, a measure of cellular energy demand, and the group
proposed that this regulation is a ΔΨm-independent mechanism to
maintain lower ΔΨm levels in higher organisms [11]. Maintenance of
lower ΔΨm levels makes sense since ROS are excessively produced at
high mitochondrial membrane potentials [12]. In addition to allosteric
regulation we and others have proposed that posttranslational
modiﬁcations, speciﬁcally reversible phosphorylation, may play an
essential role in the regulation of OxPhos andΔΨm. However, very little
is known about the effect of cell signaling pathways on OxPhos.
Nineteen phosphorylation sites have been mapped in mammalian
OxPhos complexes and Cytc, but signaling pathways including the
immediate upstream kinases and phosphatases involved in these
posttranslationalmodiﬁcations remain unknown inmost instances (for
recent reviews see [13,14]). Among those phosphorylation sites
identiﬁed are ﬁve tyrosine residues: Y75 of the δ-subunit of ATP
synthase [15], which is located in the mitochondrial matrix as is Y11 of
CcO subunit IV [16], andY304of CcO catalytic subunit I [17,18], CytcY48
[19], andCytcY97 [20],whichareaccessible fromand located in the IMS
as is SHP2. CcO Y304, Cytc Y48, and Cytc Y97 phosphorylation leads to
an inhibition of enzyme activity, and dephosphorylation of any of these
sites would lead to increased respiration.
We here show that CcO activity is signiﬁcantly increased in
lymphoblast cell lines from NS patients, as well as in mouse
embryonic ﬁbroblasts (MEFs) containing the NS-causing mutation
D61G. Using the latter cell line we show that CcO and Cytc are
downregulated at the protein level in contrast to the other OxPhos
complexes. ATP levels are lower in D61G cells compared to controls
and ROS are increased, which is also reﬂected in increased
mitochondrial damage and changes of ROS scavenging enzymes. We
discuss these ﬁndings in light of alterations of energy and ROS as a
possible contributor to the pathology of NS.
2. Materials and methods
2.1. Cell lines
Epstein Barr virus transformed human lymphoblast (B-cell) lines
from two control and two NS patients with mutations in SHP2
(patient 1: A317C, Asp106→Ala; patient 2: A922G, Asn308→Asp)were grown in DMEM media supplemented with 10% fetal bovine
serum (FBS) and 1× penicillin/streptomycin/L-glutamine (Invitro-
gen) at 37 °C in a 5% CO2 atmosphere. Mouse embryonic ﬁbroblasts
(MEFs) derived from wild-type mice (WT), D61G mutant mice, and
SHP2 knockdown mice lacking exon 3 (Ex3−/−; knockdown, KD)
have been extensively characterized in the past [21–23] and were
cultured in DMEM media supplemented as above.
2.2. Western blot analysis
Cultured cells were washed with PBS and collected by trypsiniza-
tion. The cells were denatured in SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer for 40 min at room temperature
under shaking. SDS-PAGE was carried out using a 10% acrylamide
Tris/glycine/SDS gel system. After gel electrophoresis, proteins were
transferred to a PVDFmembrane (0.2 μm, Bio-Rad, Hercules, CA) using
transfer buffer (25 mM Tris base, 192 mM glycine, 20% methanol and
0.01% SDS) for 60 min at 25 V. The membrane for Cytc detection was
UV-cross linked (Stratagene, UV Stratalinker 1800, 240 mJ) before
blocking to enhance the retention of Cytc on the membrane. The
membrane was blocked in 10% nonfat dry milk (NFDM)/PBS
overnight at 4 °C without shaking. The membrane was washed with
PBS for 5 min and incubated with primary antibodies for 2 h at room
temperature under shaking. The dilution conditions for primary
antibodies are as follows: 1:2000 dilution in PBS–Tween 20 (0.1%):
anti-Cytc (556433, BD Pharmingen), anti-MnSOD (ab13534, Abcam,
Cambridge, MA) and anti-GAPDH (G8795, Sigma-Aldrich, St. Louis,
MO); 1:5000 dilution in PBS–Tween 20 (0.1%): anti-OxPhos complex I
NDUFB6 subunit (MS108, MitoSciences, Eugene, OR), anti-OxPhos
complex III subunit core I (MS303, MitoSciences), anti-OxPhos
complex IV subunit I (MS404, MitoSciences), anti-OxPhos complex
V α subunit (MS502, MitoSciences), and anti-porin (MSA03, Mito-
Sciences); 1:8000 dilution in PBS–Tween 20 (0.1%): anti-β actin
(4970, Cell Signaling Technology, Danvers, MA); 1:1000 dilution in 5%
NFDM/PBS–Tween 20 (0.1%): anti-OxPhos complex II subunit 70 kDa
Fp (MS204, MitoSciences) and anti-CuZnSOD (574597, Calbiochem,
Madison, WI); 1:200 dilution in 5% NFDM/PBS–Tween 20 (0.1%):
anti-GPx-1 (sc-22145, Santa Cruz Biotechnology, Santa Cruz, CA). The
membranes were washed in PBS–Tween 20 (0.1%) two times for
10 min. The dilution conditions for secondary antibodies are the
following: 1:5000 dilution of anti-mouse IgG-horse radish peroxidase
(HRP) conjugated (GE Healthcare, Piscataway, NJ) in PBS–Tween 20
(0.1%): anti-OxPhos complex I NDUFB6 subunit, anti-OxPhos complex
III subunit core I, anti-OxPhos complex IV subunit I, anti-OxPhos
complex V subunit α, anti-porin, and anti-Cytc; 1:7000 dilution of
anti-mouse IgG-HRP conjugated in PBS–Tween 20 (0.1%): anti-
GAPDH; 1:5000 dilution of anti-rabbit IgG-HRP conjugated (GE
Healthcare) in PBS–Tween 20 (0.1%): anti-MnSOD; 1:8000 dilution
of anti-rabbit IgG-HRP conjugated in PBS–Tween 20 (0.1%): anti-β
actin; 1:5000 dilution of anti-mouse IgG-HRP conjugated in 5%
NFDM/PBS–Tween 20 (0.1%): anti-OxPhos complex II subunit 70 kDa
Fp; 1:5000dilution of anti-sheep IgG-HRP conjugated (SantaCruz) in 5%
NFDM/PBS–Tween 20 (0.1%): anti-CuZnSOD; 1:1000 dilution of anti
goat IgG-HRP conjugated in 5% NFDM/PBS-Tween 20 (0.1%): anti-GPx-
1. The membranes were incubated with antibodies for 1 h at room
temperature under shaking and washed in PBS–Tween 20 (0.1%) two
times for 10 min. Signals were detected by the chemiluminescence
method (ECL+ kit, GE Healthcare), and band intensities were quantiﬁed
using the program ImageQuant version 5.1 (Molecular Dynamics,
Sunnyvale, CA).
2.3. CcO activity measurements
CcO activity was analyzed in a closed 200 μL chamber equipped
with a micro Clark-type oxygen electrode (Oxygraph system,
Hansatech). Cultured cells were washed with phosphate buffered
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collected by centrifugation (500×g, 5 min), washed once more with
PBS, and sonicated as described [18]. Measurements were performed
in measuring buffer (10 mM K-HEPES (pH 7.4), 40 mM KCl, 1% Tween
20, 2 μM oligomycin, 1 mM PMSF, 10 mM KF, 2 mM EGTA) in the
presence of 20 mM ascorbate and increasing amounts of cow heart
Cytc. Oxygen consumption was recorded on a computer and analyzed
with the Oxygraph software. Protein concentration was determined
with the DC protein assay kit (Bio-Rad). CcO activity is deﬁned as
consumed O2 (μM)/min·total protein (mg).
2.4. Mitochondrial membrane potential measurements
The mitochondrial membrane potential of intact cells was
measured as described [24] with modiﬁcations. Cultured cells were
washed with PBS and trypsinized. The concentration of cells was
adjusted to 0.2 mg/mL protein with DMEMmedia without phenol red
(21063, Gibco–Invitrogen, Carlsbad, CA) and not supplemented with
fetal bovine serumandantibiotics. Tetramethylrhodamine-methylester
(20 nM) (TMRM, T-668, Molecular Probes–Invitrogen) was added to
the cell suspension.As a control, themitochondrialmembranepotential
was dissipated using 1 μM carbonyl cyanide 4-(triﬂuoromethoxy)
phenylhydrazone (FCCP). The samplewas incubated at 37 °C for 30min
in the dark under slow rotation (e.g., in a hybridization oven). Yellow
ﬂuorescence (excitation, 532 nm laser; emission, 585 nm; band pass,
42 nm)was measured using a BD FACS Array (BD Biosciences, San Jose,
CA), and data were analyzed with WinMDI version 2.9 software. The
TMRMﬂuorescencewasnormalized toﬂuorescence ofMitoTracker Red
CMXRos (M-7512, Molecular Probes–Invitrogen). MitoTracker Red
accumulates in ﬁbroblast mitochondria in a membrane potential-
independent manner. Conditions for treatment and measurement of
the cells were identical to experiments with TMRM, except the cells
were incubated with 30 nM MitoTracker Red instead.
2.5. Spectrophotometric measurement of citrate synthase activity
Citrate synthase (CS) activity was analyzed by a spectrophoto-
metric assay as described [25]. Brieﬂy, 0.1 mg of cells were solubilized
with 0.1% of dodecyl maltoside in media containing 100 mM Tris–Cl
(pH 8.1), 0.1 mM dithionitrobenzoic acid, and 50 μM acetyl-CoA. The
reaction was started with 0.5 mM oxaloacetic acid and changes of
absorbance at 412 nm were read for 1 min. Enzyme activity was
calculated from the absorbance data using an extinction coefﬁcient of
ɛ412=13.6 mM−1 cm−1.
2.6. Bioluminescent determination of ATP concentrations
Cultured cells were collected by scraping and immediately stored
in aliquots at−80 °C until measurement. ATP was released using the
boiling method by addition of 300 μL boiling buffer (100 mM Tris–Cl
(pH 7.75), 4 mM EDTA) and immediately transferred to a boiling
water bath for 2 min. Samples were put on ice, sonicated, and diluted
100-fold. Fifty microliters were used to determine the ATP concen-
tration using the ATP bioluminescence assay kit HS II (Roche)
according to the manufacturer's protocol. Experiments were per-
formed in triplicates and data were standardized to the protein
concentration using the DC protein assay kit (Bio-Rad).
2.7. Reactive oxygen species measurements
Cells were trypsinized, collected by centrifugation, washed as
above, and incubated with the ROS-sensitive probe 2′,7′-dichlorodi-
hydroﬂuorescein diacetate (H2DCFDA; D-399, Molecular Probes) at a
ﬁnal concentration of 7.5 μM for 20min at 37 °C in the dark. Cells were
collected by centrifugation, supplemented with media and incubated
in the dark for 20min at 37 °C. As a control, cells were incubated in thepresence of 100 μM H2O2. Cells were collected by centrifugation,
resuspended in PBS, transferred to a 96-well plate (Costar 3603;
200 μL per well), and analyzed on an Ascent Fluoroskan plate reader
(488 nm excitation; 527 nm emission) as described [26]. Experiments
were performed in triplicates and data were standardized to the
protein concentration determined as above.
2.8. Aconitase activity measurements
The aconitase activity was measured as a parameter of oxidative
damage in cells according to Bulteau et al. [27] with several modiﬁca-
tions. Aconitase catalyzes citrate to isocitrate and the isocitrate is
subsequently decarboxylated to α-ketoglutarate by isocitrate dehydro-
genase. NADPH is a byproduct of the latter process and the rate of
NADPHproductionwasmeasured at340nmusing a spectrophotometer
(Jasco V-570). Cultured cells were washed with PBS, collected by
trypsinization, and kept on ice until the assaywas performed. Cellswere
diluted to 2.5mg/mL ﬁnal protein concentration in solubilization buffer
(25 mM KH2PO4 (pH 7.25), 2 mMMnCl2, 0.1% dodecyl maltoside) and
incubated at room temperature for 2 min. The sample was centrifuged
(14,000 rpm for 2 min) and the supernatant was transferred to a
quartz cuvette. Isocitrate dehydrogenase (4.25 U/mL, Sigma, I2002)
and NADP+ (2 mM) were added and mixed. NADPH production was
monitored at 340 nm for 5 min by addition of 1 mM sodium citrate.
Basal NADPH production due to the endogenous citrate was measured
without addition of sodium citrate at 340 nm for 5 min and subtracted
from the experimental data. The NADPH concentration was calculated
using extinction coefﬁcient ɛ340 nm=6.22 mM−1 cm−1.
2.9. Catalase activity measurements
Catalase activity was measured as described [28] with modiﬁca-
tions. Degradation of H2O2 by catalase was monitored spectrophoto-
metrically at 240 nm as catalase activity. The cultured cells were
washed with PBS, collected by trypsinization and kept on ice until the
assay was performed. The cells were solubilized to 0.4 mg/mL protein
concentration in 50 mM KH2PO4 (pH 7.25), 0.1% dodecyl matoside at
room temperature for 2 min. The sample was centrifuged at
14,000 rpm for 2 min and the supernatant was transferred to a quartz
cuvette. The absorbance at 240 nm was monitored for 3 min after the
addition of H2O2 to a ﬁnal concentration of 8.82 mM. The decrease of
H2O2 was determined using an extinction coefﬁcient of ɛ240 nm=43.6
M−1 cm−1. Basal absorbance at 240 nm was measured at the end of
the assay by addition of NaN3, which inhibits catalase, and subtracted
from the experimental data.
2.10. Statistical analysis
Data are presented as mean±standard error of the mean (SEM).
One-way analysis of variance (ANOVA) was used to determine
statistical signiﬁcance between groups.
3. Results
3.1. Cytochrome c oxidase activity is increased in lymphoblast cell lines
derived from Noonan patients and mouse ﬁbroblasts carrying the
Noonan syndrome-causing Asp61 to Gly (D61G) mutation
Since SHP2 also localizes to the mitochondrial IMS, OxPhos
complexes may be direct or indirect targets of SHP2. CcO is a possible
direct target of SHP2 since we and others have shown that it can be
tyrosine phosphorylated on the IMS side on tyrosine 304 of subunit I
[17,18] andona yet to bemapped tyrosine residueof subunit II [29]. CcO
subunits III and IVmay also contain additional phosphorylated tyrosine
residues located on the IMS side since very strong signalswere obtained
with a phosphotyrosine-speciﬁc antibody using isolated CcO [16].
Fig. 1. Cytochrome c oxidase activity is increased in Noonan syndrome cell lines. (A)
CcO activity of cell homogenates of lymphoblast cell lines from Noonan patients
(patient 1, ♦: A317C (Asp106Ala); patient 2, ▴: A922G (Asn308Asp)) and controls
(open symbols, □ and ○) was analyzed with the polarographic method by increasing
the amount of substrate cytochrome c. (B) CcO activity of mouse ﬁbroblast cell lines
from control (□), SHP2 knockdown (⁎), and Asp61Gly (●), a mutation found in Noonan
patients. CcO activity is deﬁned as consumed O2 [μM]/min/protein [mg]. Shown are
representative measurements for each cell line (three replicates each, analyzed on the
same day; standard deviation b4% at maximal turnover). Higher amounts of cow
cytochrome c are necessary to stimulate human CcO (A) compared to mouse CcO (B) as
a result of the imperfect match [55].
Fig. 2. Expression analysis of OxPhos complexes and cytochrome c. (A) Western blot
analysis of primary antibodies were as follows. complex I: anti-NDUFB6, complex II:
anti-70 kDa ﬂavoprotein, complex III: anti-core I, complex IV: anti-subunit I, complex V:
anti-α subunit, GAPDH: glyceraldehyde 3-phosphate dehydrogenase. (B) Quantitative
assessment of protein levels by densitometric analysis of Western blots normalized to
GAPDH (n=3). Among OxPhos components, CcO and Cytc levels are 37% (pb0.02, ⁎⁎)
and 28% (p=0.05, ⁎) reduced in D61G cells.
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with NS caused by mutations in SHP2. Patient 1 has an A317C
transversion leading to the change of aspartate 106 to alanine, which
is located in the linker domain between the N- and C-terminal SH2
domains of SHP2. This patient had some features also reported in
children with mitochondrial disorder including growth delay,
developmental delays attributed to hypotonia, short stature, and
ptosis. Patient 2 has an A922G transition causing a change of
asparagine 308 to aspartate, which is located in the protein tyrosine
phosphatase domain. This patient also had some features reported in
children with mitochondrial disorder including failure to thrive and
short stature. In comparison to the controls, CcO activity was 116%
and 74% increased at saturating substrate Cytc concentrations in
patients 1 and 2, respectively (Fig. 1A, compare closed and open
symbols). At lower and intermediate Cytc concentrations CcO activity
was up to threefold increased in both patient cell lines compared to
the controls.Consistent with the above ﬁnding, similar results were obtained
withmouse embryonicﬁbroblast (MEF) cells containing theNS-causing
D61Gmutation, which showed 63% increased CcO activity compared to
controls (Fig. 1B). For this studywe also includedSHP2knockdown cells
lacking exon 3 as an additional control. These cells express a mutant
form of SHP2,which contains the intact phosphatase domain, but target
recognition is abolished. These cells showed intermediate CcO activities
(increased by 37% compared to controls, Fig. 1B).
For all subsequent experiments we used MEF cell lines, because
lymphoblasts contain fewer mitochondria and grow in clumps. In
particular, separating cells from such cell aggregates, as required for
some of the experiments shown below, triggers cell death.
3.2. Cytochrome c oxidase and cytochrome c levels are decreased in
D61G cells
Increased CcO activity might be explained by increased CcO levels.
We performed Western blot analysis for all OxPhos complexes and
Cytc, and porins, which are constituents of the outer mitochondrial
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in D61G cells after normalization to GAPDH (Fig. 2). Interestingly,
there was no signiﬁcant change in the protein levels of the other
OxPhos complexes except Cytc and porins that were decreased by 28%
and 19% in D61G and increased by 25% and 15% in SHP2 knockdown
cells (Fig. 2B). Since CcO amount is reduced in D61G cells and CcO
activity is increased, data presented in Fig. 1, which are standardized
to total protein, are an underestimation of CcO speciﬁc activity. Since
increased CcO activity cannot be explained by concomitant changes in
protein levels, alterations in posttranslational modiﬁcations may
account for increased CcO activity. We have previously shown that
phosphorylation of Y304 of CcO catalytic subunit I has a profound
effect on CcO activity, such that phosphorylation leads to strong
enzyme inhibition [17,18]. We have generated an antibody that
speciﬁcally recognizes the pY304 epitope [17] and which, to our
knowledge, is the only available antibody to a phosphoepitope
mapped on CcO. We assessed possible changes in Y304 phosphory-
lation after 2D gel electrophoresis and Western analysis, but did not
observe changes in subunit I Y304 phosphorylation (data not shown;
see Discussion).
3.3. D61G cells have decreased citrate synthase activity, decreased ATP
levels, and lower mitochondrial membrane potentials
Determination of citrate synthase (CS) activity, a marker of
mitochondrial mass, revealed 17% and 24% decreased CS activity levels
for D61G and SHP2 knockdown cells (Fig. 3A). Changes in mitochon-
drial mass and CcO activity (Fig. 1) may result in alterations in
mitochondrial functionality. We ﬁrst analyzed cellular energy levels in
D61G cells and observed 33% lower ATP levels than in wild-type,Fig. 3. (A) Citrate synthase (CS) activity measurements. Solubilized cells were incubated wit
CoA-DTNB was detected at 420 nm spectrophotometrically. CS activity was 17% and 24% redu
ATP content was determined with the bioluminescent method andwere 33% and 9% reduced
potential measurements using TMRM via ﬂow cytometry analysis (n=4). TMRM ﬂuoresce
independent mitochondrial marker in these cells. D61G cells show a 61% reduction in ﬂuorewhereas SHP2 knockdown cells showed a less dramatic decrease of 9%
(Fig. 3B). Themitochondrialmembrane potentialΔΨm is the functional
link between the proton pumps of the ETC and ATP synthase that
utilizes the electrochemical gradient to produce ATP. We analyzed
ΔΨm with the membrane potential sensitive ﬂuorescent probe TMRM
by ﬂow cytometry and normalized the resultant data to mitochondrial
mass using the mitochondria-selective probe MitoTracker Red, which
is not dependent on ΔΨm in the three cell lines (data not shown).
Strikingly, we observed a 61% reduction in TMRM ﬂuorescence inD61G
cells indicating a decreased ΔΨm (Fig. 3C).
3.4. D61G cells show increased amounts of reactive oxygen species (ROS)
ROS cause cellular damage but also serve as signaling components.
ROS have been implicated in numerous human diseases and can cause
developmental abnormalities and therefore must be well regulated
during gestation since they might otherwise interfere with organ
development (see Discussion). We speculated that ROS may be
altered in NS and analyzed ROS content using the ROS-sensitive probe
CM-H2DCFDA. Strikingly, ﬂuorescence was 75% increased in D61G
cells indicating increased ROS levels, whereas SHP2 knockdown cells
show a 27% reduced ﬂuorescent signal compared to controls (Fig. 4A).
3.5. Effect of SHP2 mutants on aconitase activity and radical
scavenging enzymes
Increased ROS as observed in D61G cells are expected to cause
cellular damage. Aconitase activity is a commonly used marker for
ROS-induced damage, because it contains an enzymatically active
[Fe4S4]2+ cluster, which is highly sensitive to ROS. Aconitase catalyzesh oxaloacetate, acetyl coA, and DTNB (5′-dithiobis-(2-nitrobenzoic acid)). Production of
ced in D61G and SHP2 knockdown cells compared to controls (n=3; pb0.005, ⁎⁎). (B)
in D61G and SHP2 knockdown cells (n=3; pb0.0001, ⁎⁎). (C)Mitochondrial membrane
nce was normalized to MitoTracker red ﬂuorescence, which is a membrane potential-
scent signal compared to controls, indicating decreased ΔΨm levels (pb0.0001, ⁎⁎).
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is located in the mitochondrial matrix. As expected, aconitase activity
was 41% reduced in D61G cells. Surprisingly, SHP2 knockdown cells
also showed, although less pronounced, 22% reduced aconitase
activity (Fig. 4D).Fig. 4. (A) Reactive oxygen species (ROS) were measured using the probe 5-(and-6)-c
Compared to controls, D61G cells show a 75% increased ﬂuorescence indicating signiﬁcantl
(n=3; pbb0.0001, ⁎⁎). As a positive control, 100 μM H2O2 was added to the cells. (B) We
peroxidase 1 (GPX-1). (C) Quantitative representation of data presented in (B). MnSOD, CuZn
D61G cells were not signiﬁcant. MnSOD levels in SHP2 knockdown cells were increased two
activities in D61G and SHP2 knockdown cells compared to controls (n=3; pb0.0001, ⁎⁎). (E)
to controls (n=3; pb0.01, ⁎⁎).As a possible consequence of increased ROS and ROS-induced
damage in D61G cells, changes in cellular defensemechanisms, speciﬁ-
cally ROS scavenging enzymes,may be expected.Weanalyzed four ROS
scavengers. Protein levels of the cytosolic copper zinc superoxide
dismutase (CuZnSOD) were similar in all three cell types (Fig. 4B andhloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate acetyl ester (CM-H2DCFDA).
y increased ROS levels whereas SHP2 knockdown cells showed a 27% decreased signal
stern blot analysis of superoxide dismutases (MnSOD and CuZnSOD) and glutathione
SOD, and GPX-1 protein levels were normalized to GAPDH. Changes in protein levels in
fold (pb0.001, ⁎⁎). (D) Aconitase activity measurements revealed 41% and 22% reduced
Catalase activity measurements showed 28% increased activity in D61G cells compared
281I. Lee et al. / Biochimica et Biophysica Acta 1802 (2010) 275–283C). The mitochondrial manganese superoxide dismutase (MnSOD) is
strongly upregulated in SHP2 knockdown cells in contrast to D61G
cells, and glutathione peroxidase levels are slightly increased in both
cell types in comparison to controls (Fig. 4B and C). Catalase is another
ROS scavenger mainly associated with peroxisomal degradation of
H2O2. We found 28% increased catalase activity in D61G cells but no
signiﬁcant increase in SHP2 knockdown cells (Fig. 4E).
4. Discussion
Tyrosine phosphatase SHP2 might be a direct link between the
MAPK pathway and OxPhos. Studies on rat brain, a tissue where SHP2
is expressed at high levels, showed partial localization of SHP2 to the
mitochondrial IMS [9]. This localization makes the OxPhos complexes
direct and indirect substrate candidates for SHP2. It is unclear how the
MAPK pathway regulates mitochondrial function. However, there is
evidence that it can affect OxPhos. For example, hearts of mice that
overexpress MKK6, a p38 MAPK activator, showed reduced levels of
all OxPhos complexes, reduced respiration rates and reduced ROS
formation [30]. In contrast, we show here that human andmouse cells
with constitutively active SHP2 have signiﬁcantly increased CcO
activities (Fig. 1), despite 37% reduced CcO levels (Fig. 2). Only the
small electron carrier Cytc showed a similar pattern with 28% reduced
protein levels, whereas the other four OxPhos complexes were not
signiﬁcantly changed.
Considering reduced CcO levels in D61G cells, CcO activity
reported in Fig. 1B is an underestimation of CcO speciﬁc activity in
D61G cells. Normalization to GAPDH protein levels (Fig. 2) or citrate
synthase activity (Fig. 3A) results in 2.7- and 2.3-fold increased CcO
activity in D61G cells, respectively, compared to controls. Down-
regulation of CcO and Cytc at the protein level may therefore reﬂect a
compensatory mechanism for increased CcO speciﬁc activity. There-
fore, our data suggest that the terminal step of the ETC, the electron
transfer from Cytc via CcO to molecular oxygen, is affected by SHP2
action.
In addition to the two tyrosine phosphorylation sites mapped on
CcO, Y304 of catalytic subunit I and Y11 of regulatory subunit IV,
several other serine and threonine sites have been mapped, which
may be downstream indirect targets of SHP2. [31–34]. Perhaps, the
most straightforward model of SHP2 action on CcO is to propose
involvement of CcO subunit II phosphorylation by Src, which leads to
an increase in CcO activity [29]. SHP2 is a positive regulator of Src, and
in vitro is able to dephosphorylate Src residue Y527, a regulatory site
located in the C-terminus region [35]. Later, an indirect mechanism
was suggested to operate in vivo via protein–protein interactions [36].
Src also localizes to the IMS [37] and can possibly interact and thus be
regulated by SHP2. Increased SHP2 activity would result in increased
Src activity, an increase of CcO subunit II phosphorylation, and
increased CcO activity. Once the phosphorylation site(s) on subunit II
have been mapped and phosphoepitope-speciﬁc antibodies are in
hand this model can stand trial.
Other signaling pathways, which have been shown to act on CcO
without knowing the precise phosphorylation sites, may be affected
by SHP2 signaling. These include PKCɛ, which was found to interact
with CcO subunit IV by co-immunoprecipitation after stimulation of
the signaling pathway followed by an increase in CcO activity
[38,39]. Another candidate pathway is epidermal growth factor
receptor (EGFR) signaling. After stimulation with EGF, EGFR was
shown to translocate to the mitochondria and to interact with CcO
subunit II [40].
Considering our ﬁnding of increased CcO activity together with a
decreased mitochondrial membrane potential in D61G cells, one
might speculate that dysregulated SHP2 activity has an effect on the
proton pumping activity of the OxPhos complexes. Previously it was
proposed that dephosphorylation of CcO could cause a “slip” of the
proton pumping activity, i.e., a decreased H+/e− stoichiometry [41],leading to a decrease of the mitochondrial membrane potential and
subsequently to reduced ATP production. Other mechanisms may be
involved, such as a proton slip in the other OxPhos complexes, or
increased proton conductancemediated by uncoupling proteins in the
inner mitochondrial membrane that have recently been shown to be
regulated by phosphorylation [42]. Decreased mitochondrial mem-
brane potential and ATP levels might also result from increased
energy demand in D61G cells, perhaps due to an increased growth
rate compared to the controls. In summary, the ﬁndings of decreased
mitochondrial membrane potential and decreased cellular ATP levels
strongly suggest an impairment of mitochondrial energy production.
The second pathological component associated with mitochon-
drial dysfunction in D61G cells is the signiﬁcantly increased pro-
duction of ROS. Generally, increased mitochondrial membrane
potential levels are associated with increased ROS production
(reviewed in [14]). However, decreased mitochondrial membrane
potential levels in combination with increased mitochondrial ROS
production have been described although the detailed mechanisms
leading to increased ROS remain elusive. For example, hexavalent
chromium, an inducer of apoptosis, was shown to trigger mitochon-
drial membrane potential depolarization in combination with
increased ROS production [43]. The Avadhani group has recently
shown in a mouse macrophage cell line that downregulation of CcO
subunit Vb leads to decreased mitochondrial membrane potential
levels in combination with increased ROS [44]. Our studies also
consistently showed a decreased mitochondrial membrane potential
but signiﬁcantly increased ROS in D61G cells (Figs. 3C and 4A), which
warrants further mechanistic studies. For example, it is possible that
other OxPhos complexes show changes in their phosphorylation
pattern, including complexes I and III, the main producers of ROS in
the OxPhos system. The known increase of ROS caused by complex I
and III inhibitors may be mimicked by (de )phosphorylations of these
complexes in vivo. On the other hand, a mitochondrial oxidative
damage marker, aconitase activity, was not dramatically decreased in
D61G cells when normalized to citrate synthase activity, and the
decrease observed may not reﬂect the signiﬁcant increase in ROS
production via DCFDA ﬂuorescence. Such increased ROS levels are
rarely found in cells from patients with mitochondrial disorders with
ROS involvement [45]. Therefore, an increase of non-mitochondrial
ROS production cannot be ruled out.
Our unprecedented ﬁndings of decreased ATP levels and increased
ROS may be important for a better understanding of the pathogenesis
of some features observed in NS. ATP is required to drive all key
cellular processes, and decreased energy levels can have a deleterious
effect on human health and performance as can be seen in traditional
mitochondrial diseases. These ﬁndings may explain, at least in part,
the features of NS that overlap with children with a primary
mitochondrial disorder including failure to thrive, hypotonia, devel-
opmental delays, short stature, ptosis, and hypertrophic cardiomyo-
pathy. Furthermore, ROS play an important role in organ development
including that of heart and brain. The participation of mitochondria in
this process becomes evident after mid-gestation when most organs
begin to grow to perform their adult function [46]. At this
developmental stage a switching occurs from energy production
that relies only 5% on aerobic metabolism before gestation day 9, to
95% after gestation day 11 as has been shown with cultured rat
embryos [47]. Interestingly, fetal antioxidant activities such as super-
oxide dismutase are depressed until just prior to parturition [48],
which might account for the increased capacity to generate ROS in
fetal tissue [46]. The importance of a narrow window of ROS
production for proper heart development and function was shown
in a study using knockout mice lacking the mitochondrial thioredoxin
reductase [49], leading to embryonic death after mid-gestation, when
switching to aerobic metabolism takes place. Although crucial for
organ development the amount of ROS must be well controlled.
Relevant examples in this context are studies using streptozotocin-
282 I. Lee et al. / Biochimica et Biophysica Acta 1802 (2010) 275–283induced animal models for diabetes, where oxidative damage caused
by ROS was found in fetuses of diabetic rats, leading to congenital
abnormalities including anomalies of the heart and great vessels, and
neuronal damage, which can in part be overcome by the application of
high doses of antioxidants, such as vitamins C and E [50,51]. Better
and more speciﬁc ROS scavengers have been developed since then,
which target ROS where they are produced. MitoQ, a ubiquinone
derivative targeted to mitochondria by covalent attachment to the
positively charged lipophilic triphenylphosphonium moiety [52], is
now in clinical trial for Parkinson's disease [53]. Other slightly
modiﬁed compounds including plastoquinonyl-decyl-triphenylphos-
phonium (SkQ1) were shown to have even better features such as
increased antioxidant activities, require lower concentrations, and
have produced remarkable results in several animal models of ROS-
induced pathologies [54]. Applications of ROS scavengers to NS
patients during pregnancy may be a future treatment to decrease
congenital abnormalities.
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